OSUR Stock Recent News
OSUR LATEST HEADLINES
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Carrie Eglinton Manner - President, CEO & Director Jason Michael Plagman - Vice President of Investor Relations Kenneth J. McGrath - Chief Financial Officer Conference Call Participants Noah Lewis - Raymond James & Associates, Inc., Research Division Operator Good day, and thank you for standing by.
OraSure Technologies (OSUR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.07 per share a year ago.
BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisition target.
BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025.
Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry.
The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research
OSUR remains deeply undervalued, trading below liquidation value, with a robust, cash-rich, debt-free balance sheet providing downside protection. Key value drivers include a 20% share buyback, potential building sale, and new product launches both in-house and via partnerships. Operational improvements—cost reductions, automation, and product diversification—should support gross margins and future growth.
OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2025 First Quarter Earnings Conference Call.